News

New prevention tools like immunization have led to major breakthroughs when it comes to respiratory diseases.
 
But respiratory syncytial virus (RSV) and pneumococcal disease remain significant health problems globally. According to a recent panel at the European Society for Pediatric Infectious Diseases (ESPID), the real power lies in how immunizations and other innovation are being rolled out.
 
From leveraging AI to optimize vaccine schedules to prioritizing monoclonal antibodies that can side-step vaccine hesitancy, the opportunities are endless.
 
But a unified call to action is needed to set these opportunities in motion—giving way to the power of community advocacy.

When we think of climate change, we usually picture melting glaciers or rising sea levels. But there’s another side to the climate crisis that doesn’t get talked about as much—how it’s helping diseases spread, including ones we already have vaccines for.
 
As our planet heats up, vaccine-preventable diseases are surfacing in places they’ve never been before.
 
But as a united front, we have the tools to fix it.
 
Read more in our latest blog. #linkinbio

SAVE THE DATE!
 
Shot@Life’s annual fall summit will be on the afternoon of September 18th. Join us virtually to get the inside scoop from global health experts, learn about new advocacy tools and tactics, and more.
 
Stay tuned to learn more and register in the coming weeks.

With support from @gavialliance, Mauritania and Senegal have become the first low-income countries to introduce the hexavalent vaccine—a 6-in-1 shot that protects against diphtheria, tetanus, pertussis, hepatitis B, Hib, and polio.
 
For families in hard-to-reach or underserved areas, combining multiple vaccines into one means fewer clinic visits, longer-lasting protection, and a lower risk of missed doses.
 
This hexavalent vaccine is more than the sum of its parts; it’s a win for children. A win for public health. A win for the future.

Vaccines save lives—and billions.
 
A new study backed by @gavialliance shows that emergency vaccine roll-outs in response to outbreaks of 5 deadly diseases (Ebola, cholera, yellow fever, measles, and meningitis) reduced deaths by nearly 60% over the past 23 years.
 
And it doesn’t stop there—here’s more of the impacts of quick and effective vaccine rollouts:
 
💸 $32 billion in economic benefits
⚡ Stopping wider outbreaks
🌍 60% reduction in cases across 210 outbreaks
 
#VaccinesWork—we cannot take them for granted. Investing in immunization is investing in global health security.

Just last week, WHO and UNICEF released their 2024 estimates of national immunization coverage. This annual report gives a snapshot of how the world is doing in protecting our youngest citizens from disease.
 
The numbers paint a clear picture: business as usual won’t be enough. Check out our latest blog to learn more—good, bad, and ugly. #linkinbio

A moment of celebration: cholera cases in Sudan have dropped by 43%—and by 12% in South Sudan.
 
This substantial decline is the result of a 10-day vaccination campaign that reached a whopping 2.24 million people. That’s a 96% coverage rate in 12 primary hot spots and 5 at-risk localities.
 
But the work doesn’t stop here; the year-long cholera outbreak that has now infected over 87,000 people needs a multi-sectoral approach to be kept at bay.
 
Access to safe water and sanitation is crucial—and this is no easy task in the middle of an ongoing humanitarian crisis. But if we act fast, we can stop this scourge in its tracks.

Feeling overwhelmed by the news lately? So are we.
 
But it’s not all bad—from novel malaria medicine developed to protect babies to the decline in reported bird flu cases, we quietly celebrate the small wins amid the turbulence.
 
Here’s a drop of good news to get your week started. ☀️☕
 
And we want to hear from you—feel free to share any and all happy health news in the comments for us to feature in the coming weeks!